Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 23 | 2024 | 1324 | 2.520 |
Why?
|
| HIV Infections | 29 | 2024 | 5097 | 1.920 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 13 | 2024 | 85 | 1.370 |
Why?
|
| Oxazines | 14 | 2024 | 81 | 1.320 |
Why?
|
| Pyridones | 14 | 2024 | 100 | 1.300 |
Why?
|
| Tenofovir | 12 | 2024 | 171 | 1.290 |
Why?
|
| Piperazines | 12 | 2024 | 82 | 1.220 |
Why?
|
| Weight Gain | 8 | 2024 | 77 | 1.000 |
Why?
|
| Developing Countries | 2 | 2024 | 400 | 0.810 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 187 | 0.740 |
Why?
|
| Benzoxazines | 7 | 2024 | 123 | 0.680 |
Why?
|
| HIV-1 | 9 | 2024 | 1260 | 0.680 |
Why?
|
| Humans | 33 | 2024 | 14537 | 0.650 |
Why?
|
| Alkynes | 6 | 2024 | 117 | 0.650 |
Why?
|
| Cyclopropanes | 6 | 2024 | 123 | 0.650 |
Why?
|
| Hypertension | 3 | 2024 | 419 | 0.490 |
Why?
|
| Adult | 16 | 2024 | 5913 | 0.450 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 146 | 0.390 |
Why?
|
| Female | 18 | 2024 | 9103 | 0.360 |
Why?
|
| Adenine | 5 | 2023 | 91 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 139 | 0.350 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2024 | 472 | 0.350 |
Why?
|
| Lamivudine | 3 | 2024 | 89 | 0.330 |
Why?
|
| Male | 14 | 2024 | 6754 | 0.310 |
Why?
|
| Pharmacogenetics | 3 | 2023 | 31 | 0.310 |
Why?
|
| Emtricitabine | 6 | 2024 | 78 | 0.290 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2024 | 33 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 244 | 0.260 |
Why?
|
| South Africa | 9 | 2024 | 7596 | 0.250 |
Why?
|
| Treatment Outcome | 3 | 2022 | 889 | 0.240 |
Why?
|
| Triazoles | 1 | 2024 | 20 | 0.240 |
Why?
|
| Obesity | 3 | 2024 | 367 | 0.240 |
Why?
|
| Middle Aged | 8 | 2024 | 3601 | 0.230 |
Why?
|
| Creatinine | 1 | 2024 | 53 | 0.220 |
Why?
|
| Viral Load | 4 | 2020 | 819 | 0.220 |
Why?
|
| Adolescent | 4 | 2024 | 2985 | 0.210 |
Why?
|
| Nitro Compounds | 1 | 2022 | 2 | 0.210 |
Why?
|
| Pyrrolidines | 1 | 2022 | 4 | 0.210 |
Why?
|
| Imidazoles | 1 | 2022 | 9 | 0.210 |
Why?
|
| Thiazoles | 1 | 2022 | 6 | 0.210 |
Why?
|
| Sofosbuvir | 1 | 2022 | 8 | 0.210 |
Why?
|
| Valine | 1 | 2022 | 6 | 0.210 |
Why?
|
| Carbamates | 1 | 2022 | 12 | 0.210 |
Why?
|
| Alanine | 4 | 2024 | 31 | 0.210 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 284 | 0.200 |
Why?
|
| Mass Screening | 1 | 2024 | 245 | 0.200 |
Why?
|
| Noncommunicable Diseases | 1 | 2023 | 77 | 0.200 |
Why?
|
| Antiviral Agents | 1 | 2022 | 111 | 0.190 |
Why?
|
| Blood Pressure | 1 | 2024 | 317 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 3 | 2023 | 551 | 0.190 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 117 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 265 | 0.180 |
Why?
|
| Pain | 1 | 2020 | 41 | 0.180 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.170 |
Why?
|
| Bone and Bones | 1 | 2019 | 38 | 0.160 |
Why?
|
| Kidney | 1 | 2019 | 46 | 0.160 |
Why?
|
| Stavudine | 1 | 2019 | 78 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 237 | 0.150 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 279 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2024 | 656 | 0.140 |
Why?
|
| Child | 1 | 2023 | 2242 | 0.140 |
Why?
|
| Africa | 3 | 2024 | 376 | 0.130 |
Why?
|
| Rilpivirine | 2 | 2024 | 7 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2024 | 1160 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 112 | 0.090 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 106 | 0.090 |
Why?
|
| Prodrugs | 2 | 2021 | 10 | 0.090 |
Why?
|
| Young Adult | 3 | 2020 | 2498 | 0.080 |
Why?
|
| RNA, Viral | 2 | 2020 | 303 | 0.080 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 322 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 188 | 0.070 |
Why?
|
| Pregnancy | 2 | 2021 | 1862 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2024 | 33 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 109 | 0.060 |
Why?
|
| Diketopiperazines | 1 | 2024 | 6 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2010 | 543 | 0.060 |
Why?
|
| Glucuronosyltransferase | 1 | 2024 | 6 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 62 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2023 | 107 | 0.050 |
Why?
|
| Interleukins | 1 | 2023 | 3 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 967 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 91 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 231 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 198 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2024 | 321 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2021 | 16 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 109 | 0.050 |
Why?
|
| RNA | 1 | 2021 | 26 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 296 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2021 | 99 | 0.050 |
Why?
|
| Genotype | 1 | 2021 | 442 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 253 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 22 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 111 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1422 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Darunavir | 1 | 2019 | 12 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 153 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 7 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 435 | 0.040 |
Why?
|
| Lopinavir | 1 | 2019 | 137 | 0.040 |
Why?
|
| Ritonavir | 1 | 2019 | 137 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 107 | 0.040 |
Why?
|
| HIV | 1 | 2021 | 380 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 197 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 272 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2021 | 799 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2019 | 278 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 1192 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 529 | 0.030 |
Why?
|
| Aged | 1 | 2019 | 1740 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2010 | 175 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 685 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 1475 | 0.020 |
Why?
|